

12 November 2018 BPC-A-28-2018

Draft agenda 28th meeting of the Biocidal Products Committee (BPC) 11-14 December 2018 ECHA Conference Centre, Annankatu 18, Helsinki Starts on 11 December at 09:30, ends on 14 December at 13:00

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-28-2018 For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-27

BPC-M-27-2018 For agreement

5. – Administrative issues

5.1. Housekeeping issues

For information

5.2. Other administrative issues and report from other Committees

BPC-28-2018-01 For information

6. – Work programme for BPC

6.1. BPC Work Programme 2018-2019 for active substance approval BPC-28-2018-02 For information

BPC Work Programme 2018-2019 for Union authorisation 6.2. BPC-28-2018-03 For information 6.3. **Outlook for BPC** BPC-28-2018-04 For information Status harmonised classification and labelling for active 6.4. substances BPC-28-2018-05 For information Status ED assessment for active substances 6.5. BPC-28-2018-06 For information

7. – Applications for approval of active substances'

7.1. Procedural and administrative aspects:

7.1.1. Template BPC opinion for active substance approval

BPC-28-2018-07 For information

7.1.2. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval

> BPC-28-2018-08 For information

- 7.1.3. Presentation of PBT status in BPC opinion: potential PBTs BPC-28-2018-09 *For discussion*
- 7.2. Draft BPC opinion on silver zinc zeolite for PT 2, 7 and 9

Previous discussion(s): TM-II-2013, TM-IV-2013, WG-III-2015, WG-III-2016, WG-V-2016, WG-V-2017; BPC-27

PT 2: BPC-28-2018-10A, B, C PT 7: BPC-28-2018-11A, B, C PT 9: BPC-28-2018-12A, B, C *For agreement*

^{*} For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.3. Draft BPC opinion on silver zeolite for PT 9 Previous discussion(s): WG-V-2017; BPC-27

BPC-28-2018-13A, B, C For agreement

7.4. Draft BPC opinion on silver copper zeolite for PT 9 Previous discussion(s): WG-V-2017; BPC-27

BPC-28-2018-14A, B, C For agreeement

7.5. Draft BPC opinion on silver sodium hydrogen zirconium phosphate for PT 9 Previous discussion(s): WG-V-2017; BPC-27

BPC-28-2018-15A, B, C For agreement

7.6. Draft BPC opinion on ADBAC and DDAC for PT 3 and 4 *Previous discussion(s): WG-V-2017*

ADBAC PT 3: BPC-28-2018-16A, B, C ADBAC PT 4: BPC-28-2018-17A, B, C DDAC PT 3: BPC-28-2018-18A, B, C DDAC PT 4: BPC-28-2018-19A, B, C *For agreement*

7.7. Draft BPC opinion on icaridine for PT 19 Previous discussion(s): WG-I-2017

BPC-28-2018-20A, B, C For agreement

7.8. Revised Assessment Report following the submission of data after active substance approval:

7.8.1. Peracetic acid for PT 1-6, 11 and 12

BPC-28-2018-21 *For agreement*

BPC-28-2018-22 For agreement

7.8.3. S-methoprene for PT 18

7.8.2. Tralopyril for PT 21

BPC-28-2018-23 *For agreement*

7.9. Requesting further information as new test guidelines become available

BPC-28-2018-24 For agreement 7.10. Systematic literature review for ED assessment

BPC-28-2018-25 For agreement

7.11. Biocides assessment and RAC opinion on harmonised classification (CLH)

BPC-28-2018-26 For agreement

Item 8 – Union authorisation**

- 8.1 Update on Union authorisation
- 8.2 Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine Previous discussion(s): WG-IV-2018

BPC-28-2018-27A, B, C, D *For adoption*

Item 9 – Any other business

Item 10 – Action points and conclusions

For agreement

^{**} For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product familiy (denoted by D).



Provisional time schedule for the 28th meeting of the Biocidal Products Committee (BPC) ECHA Conference Centre, Annankatu 18, Helsinki 11 December 2018: starts at 09:30; 14 December 2018 ends at 13:00

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, followup discussions may take place on the following day for BPC opinions.

Tuesday 11 December: morning session

Items 1-5	Opening	items and administrative issues		
Item 6		gramme of the BPC 2018-2019		
	6.1.	BPC Work Programme 2018-2019 for active substance approval		
	6.2.	BPC Work Programme 2018-2019 for Union authorisationl		
	6.3.	Outlook for BPC		
	6.4.	Status harmonised classification and labelling for active substances		
	6.5.	Status ED assessment for active substances		
Item 7.1.	Procedur	al and administrative aspects:		
	7.1.1.	Template BPC opinion for active substance approval		
	7.1.2.	Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval		
	7.1.3.	Presentation of PBT status in BPC opinion: potential PBTs		
Tuesday 11 December: afternoon session				
Item 7.2-7.5	BPC opin	ions on silver:		
	7.2.	Draft BPC opinion on silver zinc zeolite for PT 2, 7 and 9		
	7.3.	Draft BPC opinion on silver zeolite for PT 9		
	7.4.	Draft BPC opinion on silver copper zeolite for PT 9		
	7.5.	Draft BPC opinion on silver sodium hydrogen zirconium		

- - phosphate for PT 9

Wednesday 12 December: morning session

Item 7.2-7.5 Draft BPC opinions on silver (cont'd)

Wednesday 12 December: afternoon session

Item 7.2-7.5 Draft BPC opinions on silver (cont'd)

Thursday 13 December: morning session

- Item 7.6. Draft BPC opinion on ADBAC and DDAC for PT 3 and 4
- Item 7.7. Draft BPC opinion on icaridine for PT 19

Thursday 13 December: afternoon session

Item 7.7	(cont'd)	
Item 7.8.		Assessment Report following the submission of data after bstance approval:
	7.8.1.	Peracetic acid for PT 1-6, 11 and 12
	7.8.2.	Tralopyril for PT 21
	7.8.3.	S-methoprene for PT 18
Item 7.9.	Requesting further information as new test guidelines become available	
Item 7.10.	Systemat	ic literature review for ED assessment
Item 7.11.	Biocides (CLH)	assessment and RAC opinion on harmonised classification

Friday 14 December: morning session

Item 8.1	Update on Union authorisation
Item 8.2	Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine
Item 9	AOB
Item 10	Action points and conclusions

End of meeting

000